PC-SPES: A Potent Inhibitor of Nuclear Factor-κB Rescues Mice from Lipopolysaccharide-Induced Septic Shock
Open Access
- 1 December 2003
- journal article
- Published by Elsevier in Molecular Pharmacology
- Vol. 64 (6) , 1521-1529
- https://doi.org/10.1124/mol.64.6.1521
Abstract
Septic shock is the most common cause of death in intensive care units, and no effective treatment is available at present. Lipopolysaccharide (LPS) is the primary mediator of Gram-negative sepsis by inducing the production of macrophage-derived proinflammatory cytokines, in which activation of nuclear factor-κB (NF-κB) plays an important role. PC-SPES is an eight-herb mixture active against a variety of malignancies, including prostate cancer and leukemia. In this study, we demonstrated that PC-SPES inhibited the LPS-induced NF-κB reporter activity in RAW264.7 macrophages. Electrophoretic mobility shift assay showed that PC-SPES inhibited the binding of NF-κB to specific DNA sequences; however, it did not affect either degradation of inhibitory κBα or nuclear translocation of NF-κB. Also, we explored the effect of PCSPES on LPS-induced mitogen-activated protein (MAP) kinase signaling; PC-SPES did not affect LPS-induced phosphorylation of MAP kinases, including c-Jun NH2-terminal kinase, p38, and extracellular signal-regulated kinase 1/2. Moreover, PC-SPES decreased the production of proinflammatory cytokines and inducible enzymes, such as tumor necrosis factor (TNF) α, interleukin (IL)-1β, IL-6, cyclooxygenase-2, as well as inducible nitric-oxide synthase in RAW264.7 macrophages and peritoneal macrophages from C57BL/6 mice after the cells were stimulated by either LPS or LPS and interferon-γ. Furthermore, PC-SPES rescued C57BL/6 mice from death caused by LPS-induced septic shock in conjunction with decreased serum levels of TNFα and IL-1β. Together, PC-SPES is a potent inhibitor of NF-κB and might be useful for the treatment of sepsis and inflammatory diseases.Keywords
This publication has 39 references indexed in Scilit:
- Toll-like receptors: how they work and what they doCurrent Opinion in Hematology, 2002
- HERBAL THERAPY PC-SPES: IN VITRO EFFECTS AND EVALUATION OF ITS EFFICACY IN 69 PATIENTS WITH PROSTATE CANCERJournal of Urology, 2000
- Nitric oxide synthase and cyclooxygenasesCurrent Opinion in Rheumatology, 1999
- Trends in Alternative Medicine Use in the United States, 1990-1997JAMA, 1998
- Clinical and Biologic Activity of an Estrogenic Herbal Combination (PC-SPES) in Prostate CancerNew England Journal of Medicine, 1998
- A novel DNA recognition mode by the NF-κB p65 homodimerNature Structural & Molecular Biology, 1998
- Role of NFkappaB in the mortality of sepsis.Journal of Clinical Investigation, 1997
- A second large controlled clinical study of E5, a monoclonal antibody to endotoxinCritical Care Medicine, 1995
- Efficacy and Safety of Monoclonal Antibody to Human Tumor Necrosis Factor α in Patients With Sepsis SyndromeJAMA, 1995
- Recombinant Human Interleukin 1 Receptor Antagonist in the Treatment of Patients With Sepsis SyndromeJAMA, 1994